Luigi Manenti

uigi Manenti joined Alentis in 2023 as Chief Medical Officer, bringing extensive international pharmaceutical experience designing and executing innovative clinical trials, particularly in translational clinical oncology as a physician and scientist.

Prior to Alentis, he served as CMO of HiFiBiO Therapeutics where he led the clinical development organization that delivered successful IND and CTA submissions and secured supply agreements for the investigational oncology drug tislelizumab.

Luigi previously served as Team Leader for Solid Tumors in Novartis’s Oncology Business Unit and at the Novartis Institutes for BioMedical Research (NIBR), the innovation engine of Novartis, as Executive Global Clinical Program Leader, leading the development of multiple programs including the cancer drug capmatinib (Tabrecta). Prior roles include several positions at Roche in Switzerland and China.

Luigi is a member of the American Society of Clinical Oncology (ASCO), has published several articles, and is a co-inventor of several patent applications.

Luigi holds an M.D. in Medicine and Surgery from the University of Pavia in Italy.